Latest Kaiser Health News Stories
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
Vaping is becoming increasingly popular in the United States, especially among young people. This fact is triggering an unexpected divide within the public health community and complicating efforts to regulate the industry.
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Restaurants, convenience stores, vending machines and pizza delivery services are among the businesses that will have to provide calories counts to consumers.
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
The ‘scary’ findings show a discouraging lack of progress in cleaning the devices, despite more vigorous efforts in the wake of deadly superbug outbreaks, experts say.
California and federal officials have cracked down on a major compounding pharmacy they say posed a threat to public safety, but their actions are worsening shortages of medications that doctors rely on to keep their patients out of pain.
Suffering Americans seek medical marijuana as an alternative to opioids and other powerful pharmaceuticals. Though legal in 29 states, some doctors say the lack of strong data makes it hard to recommend.
Kaiser Health News reporter Sarah Jane Tribble sat down with Food and Drug Administration Commissioner Scott Gottlieb on C-SPAN’s “Newsmakers” program. The conversation ranged from how the nation should combat the opioid epidemic to reining in drug prices.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Margot Sanger-Katz of The New York Times discuss the apparent demise of bipartisan legislation aimed at shoring up parts of the Affordable Care Act. They also discuss aggressive new efforts by the Food and Drug Administration to regulate tobacco products. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
In a historic move, the Food and Drug Administration stated its intent Thursday to require tobacco companies to cut nicotine levels in their products to make them less addictive. Stripping cigarettes of addictive power could lead an estimated 5 million adults to quit smoking within a year of the plan.
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
For some federal health programs, a shuttered government means business as usual. But the congressional impasse over funding will hit others hard.
The Republican senator sent out letters to the Food and Drug Administration and HHS demanding an explanation about a rogue herpes vaccine trial.
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Controversial research methods by university researcher unlikely to prompt federal response or institutional change, experts say.
Some of the nation’s most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
Medicines are up to 80 percent cheaper north of the border and overseas, so U.S. localities are greasing a pharmaceutical pipeline that the feds warn is illegal and possibly unsafe.